Home/Pipeline/FAP Prodrug Program

FAP Prodrug Program

Cancer

PreclinicalActive

Key Facts

Indication

Cancer

Phase

Preclinical

Status

Active

Company

Tract Bio

About Tract Bio

Tract Bio is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, USA. Its core asset is the stemECHO platform, a proprietary technology for cloning and studying epithelial stem cells with high genetic fidelity, which it uses to discover novel therapeutic targets in cancer and inflammatory diseases. The company is building a preclinical pipeline focused on targeting pathogenic stem cells and utilizing a fibroblast-activated protein (FAP) prodrug strategy. Tract Bio's strategy involves internal pipeline development and seeking partnerships with established industry leaders.

View full company profile

Therapeutic Areas

Oncology Inflammatory Diseases

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active